Posted on February 14th, 2012 by
Complete Genomics Inc. (GNOM) was chosen by Mayo Clinic's Center for Individualized Medicine to provide whole human genome sequencing outsourcing services, to supplement the nonprofit research hospital's in-house gene-sequencing laboratory. Complete Genomics shares rose nearly 24% to $4.07 in recent premarket trading. Through Friday's close, the stock is up nearly 49% from its all-time low in January, as the sector received a big lift from Swiss drug giant Roche Holding Ltd.'s (ROG.VX) hostile offer for Illumina Inc. (ILMN), which makes tools for DNA sequencing.
Wall Street Journal, 02/13/2012
You must be logged-in to the site to post a comment.